Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review
Computational and Structural Biotechnology Journal
; 20:3533-3544, 2022.
Article
in English
| Web of Science | ID: covidwho-1977168
ABSTRACT
Both novel and conventional vaccination strategies have been implemented worldwide since the onset of coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite various medical advances in the treatment and prevention of the spread of this contagious disease, it remains a major public health threat with a high mortality rate. As several lethal SARS-CoV-2 variants continue to emerge, the development of several vaccines and medicines, each with certain advantages and disadvantages, is underway. Additionally, many modalities are at various stages of research and development or clinical trials. Here, we summarize emerging SARS-CoV-2 variants, including delta, omicron, and "stealth omicron," as well as available oral drugs for COVID-19. We also discuss possible antigen candidates other than the receptor-binding domain protein for the development of a universal COVID-19 vaccine. The present review will serve as a helpful resource for future vaccine and drug development to combat COVID-19.(c) 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http//creativecommons.org/licenses/by-nc-nd/4.0/).
Full text:
Available
Collection:
Databases of international organizations
Database:
Web of Science
Topics:
Vaccines
/
Variants
Language:
English
Journal:
Computational and Structural Biotechnology Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS